
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
In this video, Michael A. Weber, MD, discusses the background and findings of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.

